Why We Can't Have Nice Things cover image

Why We Can't Have Nice Things: The War on Drugs

Why We Can't Have Nice Things

00:00

MDMA Therapy and the FDA: A Complex Journey

This chapter explores the recent FDA ruling on MDMA for treating PTSD, emphasizing its potential to enhance psychotherapy by addressing fear and trauma. It critiques the FDA's cautious stance, reflecting on the implications for those in need of innovative treatments and the contrast with past opioid approvals. The discussion highlights the challenges faced by the psychedelic research community amidst strict regulations and the risks associated with unregulated drug access.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app